ArticleCureus2026
Metabolic Benefits of Saroglitazar 4 mg in Type 2 Diabetes Mellitus With Dyslipidemia: A Retrospective Real-World Observational Cohort Study From India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background This retrospective real-world study evaluated saroglitazar 4 mg in Indian adults with type 2 diabetes mellitus (T2DM) and dyslipidemia. Methods Six hundred patients receiving saroglitazar 4 mg at Dr Aravind's Diabetes Centre, Bengaluru, were assessed at baseline, four months, and six months. Glycemic, lipid, hepatic, FibroScan, renal, and anthropometric parameters were analyzed using paired t-tests. Results Significant improvements were observed across all outcomes (p<0.0001). Fasting blood sugar (FBS) decreased by 101.81 mg/dL, postprandial blood sugar (PPBS) by 111.58 mg/dL, and HbA1c from 8.90% to 7.61%. Triglycerides reduced by 163.34 mg/dL, high-density lipoprotein cholesterol (HDL-C) increased by 9.25 mg/dL, and total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) decreased. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), controlled attenuation parameter (CAP) score, liver stiffness measurement (LSM), serum creatinine, estimated glomerular filtration rate (eGFR), and body weight also improved. Conclusion Saroglitazar 4 mg significantly improved glycemic, lipid, hepatic, renal, and weight-related outcomes over six months in patients with T2DM and dyslipidemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.